Amgen Inc. (NASDAQ:AMGN) Shares Sold by Marco Investment Management LLC

Marco Investment Management LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 6.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 36,109 shares of the medical research company’s stock after selling 2,310 shares during the quarter. Marco Investment Management LLC’s holdings in Amgen were worth $10,400,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of AMGN. Briaud Financial Planning Inc purchased a new stake in shares of Amgen during the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of Amgen during the 4th quarter worth $29,000. OFI Invest Asset Management purchased a new stake in shares of Amgen during the 3rd quarter worth $26,000. Planned Solutions Inc. purchased a new stake in shares of Amgen during the 4th quarter worth $30,000. Finally, Providence Capital Advisors LLC purchased a new stake in shares of Amgen during the 3rd quarter worth $30,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on AMGN. Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. TD Cowen decreased their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Raymond James started coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. Finally, UBS Group decreased their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Trading Up 0.2 %

Shares of NASDAQ AMGN traded up $0.60 on Friday, reaching $269.98. 2,436,959 shares of the company traded hands, compared to its average volume of 2,035,139. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a 50 day moving average of $275.10 and a 200 day moving average of $281.51. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the prior year, the company posted $4.09 EPS. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. On average, equities research analysts forecast that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.